復宏漢霖(02696.HK):完成地舒單抗生物類似藥HLX14第1期臨床研究
復宏漢霖(02696.HK)公布,近日完成一項自主研發的地舒單抗生物類似藥HLX14在中國男性健康受試者中開展的1期臨床研究。研究結果表明,HLX14與不同來源參照藥的藥物代謝動力學特徵和藥效學具有高度相似性,安全性、耐受性和免疫原性均可比。該研究達到了所有預設的研究終點。
HLX14是公司自主研發的地舒單抗注射液生物類似藥,擬用於治療骨折高風險的絕經後婦女的骨質疏鬆症及╱或與原研藥藥品標籤相符的其他適應症。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.